On the evening of September 13, 2016, Dr. Lu Xianping, the president and chief scientific officer of CHIPSCREEN BIOSCIENCES, was invited to come to the academic report hall of Jiangning campus of China Pharmaceutical University to give a report entitled " innovation to meet clinical needs: from basic research to the listing of new drugs" to more than 400 teachers and students in the first phase of the " lecture hall for one thousand ". The first talk was full of audiences on the scene, even the corridor was packed with teachers and students who came to listen.

In this report, Dr. Lu Xianping tells us that after 12 years of painstaking research, the CHIPSCREEN BIOSCIENCES team has finally developed a new anti-cancer drug with independent intellectual property rights in China, which is China's first original new drug authorized for patent use in developed countries such as the United States - Chidamide. This means that China has its own original new anti-cancer drug. China's drug research and development has gradually entered from the stage of imitation to independent innovation at the same level as developed countries and even ahead. He also shared with everyone the key to his pioneering path of new drugs in China: "simple" and " naive".

Fifteen years ago, Lu Xianping, who was in the United States, talked with his friends about the development of China's pharmaceutical industry: " our country has very outstanding scientists, enormous markets and good pharmaceutical infrastructure. The pharmaceutical industry should not be at the bottom of the ecological chain. " Then he gave up the excellent working environment in the United States, bid farewell to his family and returned home alone, not for fame and fortune, but for the soil and water of that party. " our idea is very simple, that is to change the current situation of China's original medicine industry. " said Dr. Lu. This is his" simplicity " as a Chinese.

Turning to the research and development of Chidamide, Lu Xianping said that when he and his team studied histone deacetylase (HDAC) in 2002, they did not know what the relationship between HDAC and epigenetics was. They only knew that HDAC was involved in the transcription control complex, which was involved in differentiation, proliferation, immune control and inflammation formation. Based on this, they speculate that HDAC is likely to affect the differentiation of tumor epithelium, so Lu Xianping and his team began their unremitting research for more than 10 years. " If this conjecture is confirmed, it will bring revolutionary changes to the treatment of tumors. " He uses time and sweat to verify it, which is his" innocence " as a scientist.

Dr. Lu Xianping's report touched the teachers and students here and won warm applause. During the on-site question-and-answer session, Dr. Lu Xianping patiently and carefully answered the questions of his classmates, and showed his own perception. The teachers and students of the Pharmaceutical University also had a warm interaction with Dr. Lu., and the students played a barrage from time to time and shared their experience in listening to lectures. The first lecture was splendid and received unanimous praise from teachers and students.

The first " lecture hall for 1,000 people" opened nationwide by China Pharmaceutical University is a completely new compulsory course for master's degree students in 2016. The purpose of this course is to " keep improving and stop at perfection". It aims at promoting postgraduates to acquire the latest professional knowledge, expand their thinking mode, broaden their knowledge scope, understand the frontier and latest developments in discipline research, and comprehensively improve the academic level of postgraduates. The teachers are academicians of both houses, experts specially appointed by the " 1000-person plan" of the Central Organization Department and scholars of the Yangtze river. They all have overseas study background and are recognized as " tycoon" by the domestic and foreign medical circles.